38 replies to this topic

[Hip]

 

Kimer Med is working on replicating the original results with DRACO, along with testing against SARS-CoV-2, to be followed by testing in mice and then clinical trials.

 

If you'd like to follow our work, consider subscribing to our email list:

 

https://kimermed.co.nz/landing

 

If anyone has questions about DRACO, I can try to answer them.

 

 

 

Very interesting. Very glad to see someone taking DRACO further. I will post links to your website on another forum I am a member of, the Phoenix Rising ME/CFS forum.

 

 

 

A question I have always wanted to ask is about DRACO's potential to treat the low-level viral infections found in many chronic diseases. 

 

Many chronic diseases have been linked to ongoing low-level infections of everyday viruses in common circulation (see this article), and people such Professor Paul Ewald believe that many non-genetic chronic diseases may well be caused by such chronic infections. If this turns out to be true, and if DRACO can target and inhibit the viral infections found in chronic diseases, then DRACO could become not only a universal antiviral, but also a means to treat numerous chronic illnesses.

 

But the chronic viral infections associated with chronic diseases are not the same as the full-blown acute viral infection you get when you catch a cold or flu. They are slow, low-level smoldering infections. 

 

In the case of enterovirus infections, the chronic low-level form of this is infection is known as non-cytolytic enterovirus, which is an intracellular infection involving low-levels of naked enteroviral ssRNA and dsRNA living in human cells on a long term basis. Diseases such as type 1 diabetes, chronic myocarditis, dilated cardiomyopathy, amyotrophic lateral sclerosis, myalgic encephalomyelitis, Crohn's disease and Parkinson's have all been linked to non-cytolytic enterovirus. Thus if we had an effect antiviral for non-cytolytic enterovirus, we might be able to cure a whole groups of chronic diseases in one fell swoop. 

 

So my question is, would DRACO be able to target such infections, even with the low-levels of dsRNA present?

Edited by Hip, 23 August 2020 - 05:18 AM.

[Kimer Med]

Very interesting. Very glad to see someone taking DRACO further. I will post links to your website on another forum I am a member of, the Phoenix Rising ME/CFS forum.

 

Thanks.

 

A question I have always wanted to ask is about DRACO's potential to treat the low-level viral infections found in many chronic diseases. 
 
Many chronic diseases have been linked to ongoing low-level infections of everyday viruses in common circulation (see this article), and people such Professor Paul Ewald believe that many non-genetic chronic diseases may well be caused by such chronic infections. If this turns out to be true, and if DRACO can target and inhibit the viral infections found in chronic diseases, then DRACO could become not only a universal antiviral, but also a means to treat numerous chronic illnesses.
 
But the chronic viral infections associated with chronic diseases are not the same as the full-blown acute viral infection you get when you catch a cold or flu. They are slow, low-level smoldering infections. 
 
In the case of enterovirus infections, the chronic low-level form of this is infection is known as non-cytolytic enterovirus, which is an intracellular infection involving low-levels of naked enteroviral ssRNA and dsRNA living in human cells on a long term basis. Diseases such as type 1 diabetes, chronic myocarditis, dilated cardiomyopathy, amyotrophic lateral sclerosis, myalgic encephalomyelitis, Crohn's disease and Parkinson's have all been linked to non-cytolytic enterovirus. Thus if we had an effect antiviral for non-cytolytic enterovirus, we might be able to cure a whole groups of chronic diseases in one fell swoop. 
 
So my question is, would DRACO be able to target such infections, even with the low-levels of dsRNA present?

 

 

DRACO directly binds to and is activated by dsRNA. In the original research, it was found effective against 4 different strains of Rhinovirus (responsible for the common cold), which are an Enteroviruses. There's no reason to believe it wouldn't also be effective against other Enteroviruses.

 

It doesn't take much dsRNA to activate the compound, and all viruses make dsRNA at some stage in their replication cycle, even those whose genome is made from ssRNA, such as Enteroviruses.

 

 

[YOLF]

 

Kimer Med is working on replicating the original results with DRACO, along with testing against SARS-CoV-2, to be followed by testing in mice and then clinical trials.

 

If you'd like to follow our work, consider subscribing to our email list:

 

https://kimermed.co.nz/landing

 

If anyone has questions about DRACO, I can try to answer them.

 

 

Of the chronic conditions listed in this post, can any not be targeted by DRACO? I seem to recall doing some light research on it and there are a handful of viruses for which DRACO won't work, perhaps because they don't produce dsRNA, or fit into some other category.

 

Is Kimer part of any listed company, does it fundraise on any of the crowdfunding investment platforms? Can you keep us updated as to new opportunities?

[Kimer Med]

Of the chronic conditions listed in this post, can any not be targeted by DRACO? I seem to recall doing some light research on it and there are a handful of viruses for which DRACO won't work, perhaps because they don't produce dsRNA, or fit into some other category.

 
Of the viruses listed on that page, they tested DRACO against:
 
Enterovirus (Rhinovirus)
Adenovirus (strain 5, though, vs. the listed 36)
Influenza A
 
All viruses produce dsRNA, so that part's not a problem.
 
However, viruses also have a range of defenses, which tend to vary from one virus to another. So far, DRACO was successful against all 15 viruses tested in the original paper. We therefore have good reason to be hopeful that it will be effective against a very broad range of additional viruses (perhaps all of them!)--but we won't know the specifics until we test.

 

Is Kimer part of any listed company, does it fundraise on any of the crowdfunding investment platforms? Can you keep us updated as to new opportunities?

Kimer Med Limited isn't part of any other company.

We are planning a crowdfunding campaign in the relatively near future, but haven't announced any dates yet.

At the moment, the best way to stay updated is join us on our free email list at https://kimermed.co.nz/landing. We are also posting regular updates and answering questions on our forum, at https://forum.kimermed.co.nz/

 

[YOLF]

Thanks,

 

What do you think will be the hardest obstacle DRACO to overcome? Biofilms, ECM modifications? Something else?

 

Also, will you be listing in the US? I think foreign investment is often prohibited, so companies have to establish entities here. On the stock market they ADRs or American Depository Receipts. Not sure what they do on the venture capital end of things though.

[Kimer Med]

Thanks,

 

What do you think will be the hardest obstacle DRACO to overcome? Biofilms, ECM modifications? Something else?

 

Also, will you be listing in the US? I think foreign investment is often prohibited, so companies have to establish entities here. On the stock market they ADRs or American Depository Receipts. Not sure what they do on the venture capital end of things though.

 

Biofilms made of viruses can actually happen. I have no idea how common they are, though. Since our compound has to get into cells to be effective, if that was prevented by a viral biofilm, that would be a good defense. Although there are a number of nutrients that are known to help dissolve bacterial biofilms, I'm not sure if similar compounds are effective against viruses.

 

Based on my understanding, I don't think the extracellular matrix (ECM) will be an issue. As long as our compound can move through it and into cells, it will still be able to function.

 

We're a long way from deciding where we will list, or even if we will list. Kimer Med Limited is a New Zealand company, and that part is unlikely to change. Even so, there are a number of SEC-approved ways that those in the US will be able to be involved, when the times comes.

Edited by Kimer Med, 01 October 2020 - 09:09 AM.

[YOLF]

Oh everyone definitely has them. We've had them since before we were primates.

 

The question is: to what extent are they expressed? We know they are expressed sometimes but I don't know how often, in what tissues, etc.

 

Something that skipped my mind early on about endogenous retroviruses is whether they are complete or just the payloads of long dead viruses? DRACO doesn't seem to kill all cells, just unhealthy cells, so it stands to reason that these would be spared.

[Kimer Med]

Something that skipped my mind early on about endogenous retroviruses is whether they are complete or just the payloads of long dead viruses? DRACO doesn't seem to kill all cells, just unhealthy cells, so it stands to reason that these would be spared.

 

DRACO can't detect viral DNA payloads and the like. The activation trigger is double-stranded RNA (dsRNA), which is present when a virus is engaged in lytic replication.

 

Cells with retroviruses that have long-ago stopped entering lytic replication won't be affected. Since most cell death, damage and impairment happens during lytic replication, that should be OK -- at least for most viruses; there may well be exceptions we don't know about yet.

[YOLF]

Well, with Trump and half of the government going into the hospital, now might be a good time to do some human safety self-experiments in people with chronic health issues.

 

How do we go about figuring out a human dose? How much do we need?